Recognising innovation in technologies, products, processes, and services to combat the impact of global healthcare emergencies on individuals, patients, healthcare professionals and communities. Including but not limited to drug or device development, rapid response, medical equipment and the introduction of services, solutions and resources to combat the impact of past and potential healthcare emergencies.

Criteria:

Innovation
How does the entry demonstrate innovation and resourcefulness in response to healthcare emergencies? Will it inspire future development?

Purpose and Outcomes
Does it achieve its purpose? Does it offer benefits to the audience it was designed for?

Problem-solving
Does the entry demonstrate a unique approach to solving a particular challenge?

Competitive Advantage
How does the entry demonstrate going above and beyond or a collaborative approach in a time of crisis?

Innovation in technologies, products, processes, and services for the development and manufacture of active pharmaceutical ingredients including, but not limited to, synthesis, characterization, scale-up, software and database development, bulk manufacturing.

Criteria:

Innovation
Does the entry introduce a new idea, method or process to the market? Will it inspire broader applications?

Purpose
Does it achieve its purpose? Does it offer clear benefits or improvements over existing solutions?

Problem-solving
Does it solve a problem? Does it address an issue in an effective way?

Competitive Advantage
Does it offer a competitive advantage in the market and within its category?

Innovation in technologies, products, processes, and services related to the formulation of drug products including, but not limited to, excipients, finished dose, OTC, novel software and digitilisation, process development, resolving formulation challenges, bioavailability enhancement, drug targeting or controlled release and stabilization technologies.

Please note: to be eligible for this category, the activity must have taken place between Jan 2022 - August 2023.

Criteria

Innovation
Does the entry introduce a new idea, method, or novelty to the market?

Purpose
Does it achieve its purpose? Does it offer clear benefits or improvements over existing solutions?

Problem-solving
Does it solve a problem? Does it address an issue in an effective way?

Competitive Advantage
Does it offer a competitive advantage in the market and within its category?

Innovation in technologies, processes, and services for the manufacture of solid, semi-solid, parenteral, inhalation, or other dosage drugs including, but not limited to, equipment, approaches,digitilisation, manufacturing processes, facilities, tech transfer and process controls. We welcome entries across both small and large molecule manufacturing.

Criteria

Innovation
Does the entry introduce a new idea, process, method, or novelty to the market? Will it inspire future development?

Features
Does the entry have unique qualities, abilities, or significantly improved attributes?

Problem-solving
Does it solve a problem? Does it address an issue in an effective way?

Competitive Advantage
Does it offer a competitive advantage in the market and within its category?

Innovation in technologies, products, solutions, processes, and services related to drug delivery, routes of administration and device innovation. Including, but not limited to, inhalers, auto-injectors, pre-filled syringes, patches, combination products, intelligent packaging and connected devices.

Criteria

Innovation
Does the entry introduce a new idea, device, method or novelty to the market? Will it inspire future development?

Features & Purpose
Does the entry have unique qualities, abilities, or improved attributes? Does it offer a significant improvement on existing market solutions?

Patient Centricity
Does the entry offer tangible improvements to patient adherence and experience?

Problem-solving
Does it solve a problem? Does it address an issue in an effective way?

Competitive Advantage
Does it offer a competitive advantage in the market and within its category?

Innovation in technologies, products, processes, equipment and services for primary, secondary and tertiary packaging solutions and the packaging and assembly of finished drug products. Including but not limited to, vials, ampules, blister packs, cartons, containers, tamper-proof packaging, labelling systems, track and trace, machinery, anticounterfeiting measures and solutions which prioritise patient centricity and adherence.

Criteria

Innovation
Does the entry introduce a new idea, device, method, or service to the market? Will it inspire future development?

Purpose
Does it achieve what it was intended to achieve? Does it offer a significant improvement on existing market solutions?

Sustainability
Has the entry been created with sustainability in mind? Does it seek to reduce carbon emissions or environmental impact?

Problem-solving
Does it solve a problem? Does it address an issue in an effective way?

Competitive Advantage
Does it offer a competitive advantage in the market and within its category?

Innovation in technologies, products, processes, and services for ensuring the safe handling, security and tracking of drug substances, raw materials, and finished drug products. Including, but not limited to, supply chain optimisation, audits, temperature-controlled logistics, transport services, shipping and storage, anticounterfeiting, inventory management, demand forecasting and distribution channels.

Criteria

Innovation
Does the entry introduce a new idea, device, method, or service to the market? Will it inspire future development?

Purpose
Does it achieve what it was intended to achieve? Does it offer a significant improvement on existing market solutions?

Problem-solving
Does it solve a problem? Does it address an issue in an effective way?

Competitive Advantage
Does it offer a competitive advantage in the market and within its category?

Recognition of sustainable manufacturing, production or development in the pharmaceutical industry. Including but not limited to, innovative approaches to reducing environmental impact, waste and carbon emissions, energy or utility saving solutions, sustainable and collaborative product development, plastic reduction, improved recyclability or lifecycle management, implementation of circular economy initiatives, innovative use of materials, safeguarding of workers, and programmes or initiatives which seek to improve diversity and inclusion.

Criteria

Innovation
Does the entry introduce a new idea, material, device, method, or service to the market? Will it inspire future development?

Purpose
Does it achieve what it was intended to achieve? Does it offer a proven improvement on existing market solutions?

Environmental Impact
Does the entry offer a demonstrable improvement in reducing carbon emissions?

Competitive Advantage
Does it offer a competitive advantage in the market and within its category?

Innovation in technologies, products, processes, and services designed to aid and ensure compliance with standards, mandates, and guidance documents established by regulatory authorities.Including, but not limited to, consulting services, development of consortia and industry groups, reference standards, educational programs, case studies, technologies, platforms and equipment.

Criteria

Innovation
Does the entry introduce a new idea, method, or service to the market? Will it inspire future development?

Process Excellence
Does the entry offer an improved process, leading to better outcomes and results?

Problem-solving
Does it solve a problem? Does it address an issue in an effective way?

Competitive Advantage
Does it offer a competitive advantage in the market and within its category?

C-Suite Executives of SME, Large Pharma/Biopharma or service providers are eligible for nomination. Attributes to be considered include, but are not limited to, financial performance, product performance, global reach, leadership skills, management capability, charitable initiatives, sustainability, regulatory compliance, profitability, vision, marketing, acquisitions, corporate strategy, and financing.

Criteria

Dynamism
Is the nominee an exemplary leader with a strong desire to achieve – are they compelling and progressive? How have they demonstrated exceptional leadership?

Achievements
Has the CEO achieved or accomplished sustained growth, improved performance, implemented robust strategies, engaged staff and customers in their current role or throughout the course of their career?

Leadership
Has the CEO demonstrated consistent personal strengths and attributes that makes them an extraordinary leader?

Contribution to the Wider Industry
Is the CEO committed to the development of the broader pharma industry – this could involve donating goods, funding, time, market insights business intelligence, or contributing to educational programmes.

A new category for 2023, the Start-Up Initiative award seeks to recognise Start-Ups and SMEs driving value and innovation across the pharma value chain. We are looking for entries which demonstrate a clear promise of innovation, growth or sustainable development in pharma.

We understand that Start-Ups are often at different stages of development, and accept entries across proof of concept, protype or commercialised stage.

Entries are reserved exclusively for organisations participating in the CPHI Start-Up Market. If you are a Start-Up who would like to take part, please visit our Start-Ups page here for more information.

Criteria

Innovation:
Does the entry introduce a new idea, device, method or service to the market? Does it drive or facilitate efficiencies?

Industry disruptor:
Does this product have the potential to disrupt the industry or become the future benchmark for innovation and change?

Sustainability:
Is this product created with sustainability in mind? Does it aim to reduce carbon emissions, waste or environmental impact?

Patient centricity:
Does the product or solution offer a significant improvement or development for patients and end users?

This award looks to recognise companies, individuals and initiatives which nurture philanthropic, ethical and community-based ventures. We welcome entries which prioritise patient engagement and centricity, promote corporate social responsibility and improve healthcare accessibility or equity.

Criteria:

Innovation
Does the entry introduce a new idea, method, or service to the market?

Contribution to the Wider Industry
Does the entry demonstratea commitment to improving the pharma industry? Will it inspire future development?

Problem-solving
Does it solve a problem? Does it address an issue in an effective way?

Outcomes
Can the entry demonstrate sufficient evidence of improved outcomes, through data, case studies or testimonials?

An award to recognise women leaders in pharma. This category celebrates those who seek to inspire and uplift colleagues and peers, are committed to supporting diversity and inclusion and act as an advocate for progression and change in pharma. 

Criteria:

Leadership & Collaboration 
Is the nominee an exemplary leader, are they compelling and progressive? Do they give a voice or platform to others through their leadership style? 

Advancement 
How has the entrant broken down barriers to create or facilitate opportunities for women in industry? Have they led initiatives or projects which promote or empower underrepresented communities? 

Inspiration 
Is the nominee seen as a role model within their organisation, or across the wider industry? Are they confident, and open to tackling difficult conversations or challenging the status quo? 

Contribution to the Wider Industry 
Has the nominee contributed to the development of a more diverse pharma industry – examples may include, thought leadership, mentorship, involvement with associations, employee initiatives, volunteering, coaching etc. 

Each generation brings a different perspective, and this award seeks to recognise those rising stars, the pharma leaders of the future bringing a fresh approach to the industry,  

Criteria 

We invite applications from candidates with a minimum of five years’ work experience within a pharma, biopharma company, academic or research institution. The entrant should be no older than 35 by the time of the Awards ceremony on 8th October 2024. 

Leadership & Collaboration 
What makes the entrant stand out as an emerging talent or leader? Examples could relate to managing teams, inspiring colleagues, taking on additional roles and responsibilities, noteworthy contributions to out-of-the-box projects, introducing new ideas, methodologies or initiatives or exceptional academic achievements. 

Recognition 
How has the nominee demonstrated outstanding performance in their role? Have they received external or internal awards or nominations, or been endorsed by colleagues or clients for their work? 

Personal Brand 
What steps has the nominee taken to build their profile, both internally within their organisations and externally? Have they contributed to scientific journals, undertaken thought leadership roles or built a significant social media presence?

Industry Involvement 
Is the nominee committed to the development of the broader pharma industry – this could involve participating in conferences or events, being a part of industry groups or associations, leading employee initiatives, volunteering, coaching etc.